Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?

Risultato della ricerca: Article

22 Citazioni (Scopus)

Abstract

In recent years, multiple strategies for eliciting anti-tumor immunity have been developed in different clinical studies. Currently, immunotherapy was clinically validated as effective treatment option for many tumors such as melanoma, non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). Some surface receptors of immune cells, called immune checkpoint receptors, may inhibit activity of proinflammatory lymphocytes, following binding with specific ligands. Cancer cells exploit these mechanisms to inactivate tumor-infiltrating lymphocytes (TILs) to escape from immunosurveillance. Among the different tumor-infiltrating immune cell populations, including leucocytes, macrophages, dendritic cells and mast cells, TILs are considered a selected population of T-cells with a higher specific immunological reactivity against tumor cells than the non-infiltrating lymphocytes. In this review we will discuss the promising role of TILs as biomarkers reflecting the immune response to the tumor, describing their potential ability to predict the prognosis and clinical outcome of immunotherapy in some solid tumors.
Lingua originaleEnglish
Numero di pagine8
RivistaCellular Immunology
Stato di pubblicazionePublished - 2018

Fingerprint

Tumor-Infiltrating Lymphocytes
Neoplasms
Immunotherapy
Lymphocytes
Immunologic Monitoring
Cell Surface Receptors
Renal Cell Carcinoma
Mast Cells
Non-Small Cell Lung Carcinoma
Dendritic Cells
Population
Immunity
Melanoma
Leukocytes
Biomarkers
Macrophages
Ligands
T-Lymphocytes

All Science Journal Classification (ASJC) codes

  • Immunology

Cita questo

@article{3e12f84f01764535a867f127e3b92ddf,
title = "Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?",
abstract = "In recent years, multiple strategies for eliciting anti-tumor immunity have been developed in different clinical studies. Currently, immunotherapy was clinically validated as effective treatment option for many tumors such as melanoma, non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). Some surface receptors of immune cells, called immune checkpoint receptors, may inhibit activity of proinflammatory lymphocytes, following binding with specific ligands. Cancer cells exploit these mechanisms to inactivate tumor-infiltrating lymphocytes (TILs) to escape from immunosurveillance. Among the different tumor-infiltrating immune cell populations, including leucocytes, macrophages, dendritic cells and mast cells, TILs are considered a selected population of T-cells with a higher specific immunological reactivity against tumor cells than the non-infiltrating lymphocytes. In this review we will discuss the promising role of TILs as biomarkers reflecting the immune response to the tumor, describing their potential ability to predict the prognosis and clinical outcome of immunotherapy in some solid tumors.",
keywords = "Immune suppression, Immunology, Immunotherapy, PD-1, PD-L1, Predictive significance, Prognosis, Tumor immunology, Tumor microenvironment, Tumor-infiltrating lymphocytes (TILs)",
author = "Angela Listi' and Lorena Incorvaia and Nadia Barraco and Giuseppe Badalamenti and Viviana Bazan and Daniele Fanale and Antonio Russo and Valentina Calo' and Bruno Vincenzi and Iovanna, {Juan Lucio}",
year = "2018",
language = "English",
journal = "Cellular Immunology",
issn = "0008-8749",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?

AU - Listi', Angela

AU - Incorvaia, Lorena

AU - Barraco, Nadia

AU - Badalamenti, Giuseppe

AU - Bazan, Viviana

AU - Fanale, Daniele

AU - Russo, Antonio

AU - Calo', Valentina

AU - Vincenzi, Bruno

AU - Iovanna, Juan Lucio

PY - 2018

Y1 - 2018

N2 - In recent years, multiple strategies for eliciting anti-tumor immunity have been developed in different clinical studies. Currently, immunotherapy was clinically validated as effective treatment option for many tumors such as melanoma, non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). Some surface receptors of immune cells, called immune checkpoint receptors, may inhibit activity of proinflammatory lymphocytes, following binding with specific ligands. Cancer cells exploit these mechanisms to inactivate tumor-infiltrating lymphocytes (TILs) to escape from immunosurveillance. Among the different tumor-infiltrating immune cell populations, including leucocytes, macrophages, dendritic cells and mast cells, TILs are considered a selected population of T-cells with a higher specific immunological reactivity against tumor cells than the non-infiltrating lymphocytes. In this review we will discuss the promising role of TILs as biomarkers reflecting the immune response to the tumor, describing their potential ability to predict the prognosis and clinical outcome of immunotherapy in some solid tumors.

AB - In recent years, multiple strategies for eliciting anti-tumor immunity have been developed in different clinical studies. Currently, immunotherapy was clinically validated as effective treatment option for many tumors such as melanoma, non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). Some surface receptors of immune cells, called immune checkpoint receptors, may inhibit activity of proinflammatory lymphocytes, following binding with specific ligands. Cancer cells exploit these mechanisms to inactivate tumor-infiltrating lymphocytes (TILs) to escape from immunosurveillance. Among the different tumor-infiltrating immune cell populations, including leucocytes, macrophages, dendritic cells and mast cells, TILs are considered a selected population of T-cells with a higher specific immunological reactivity against tumor cells than the non-infiltrating lymphocytes. In this review we will discuss the promising role of TILs as biomarkers reflecting the immune response to the tumor, describing their potential ability to predict the prognosis and clinical outcome of immunotherapy in some solid tumors.

KW - Immune suppression

KW - Immunology

KW - Immunotherapy

KW - PD-1

KW - PD-L1

KW - Predictive significance

KW - Prognosis

KW - Tumor immunology

KW - Tumor microenvironment

KW - Tumor-infiltrating lymphocytes (TILs)

UR - http://hdl.handle.net/10447/291123

UR - http://www.elsevier.com/inca/publications/store/6/2/2/8/0/4/index.htt

M3 - Article

JO - Cellular Immunology

JF - Cellular Immunology

SN - 0008-8749

ER -